Patients’ recruitment to the ongoing HER2‐low‐positive clinical trials which are testing the effect of ADCs in BC are based on the existing definition of HER2 categories, as described in the American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP).6 Here, ERBB2 is linked to breast cancer.